Univ.-Prof. Dr. Klaus Kopka (HZDR, Germany) is a radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at Dresden University of Technology (TUD), Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR] [https://www.hzdr.de/db/Cms?pNid=130]. Between 2013 and 2019 he held a W3 position at Ruprecht-Karls-University of Heidelberg, Germany. At the same time he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. In 2018 Klaus Kopka was honoured together with his colleagues Michael Eisenhut, Matthias Eder and Uwe Haberkorn with the highly recognized “The Stifterverband Science Award – Erwin Schrödinger Prize” of the Helmholtz Association. He was involved in the development of the theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), PSMA-914 and PSMA-1007 (approved as Radelumin). His research interests focus on radiopharmaceutical cancer research and radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide production and radionuclide theranostics; targeted endoradiotherapy; and noninvasive molecular imaging. His scientific output includes more than 275 publications (Scopus) and over 20 and 45 (EPO & USPTO) published patent monographs, respectively.
Univ.-Prof. Dr. Klaus Kopka (HZDR, Germany) is a radiopharmaceutical chemist and holds a full professorship (W3) for Bioinorganic and Radiopharmaceutical Chemistry at Dresden University of Technology (TUD), Germany, which is combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR] [https://www.hzdr.de/db/Cms?pNid=130]. Between 2013 and 2019 he held a W3 position at Ruprecht-Karls-University of Heidelberg, Germany. At the same time he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. In 2018 Klaus Kopka was honoured together with his colleagues Michael Eisenhut, Matthias Eder and Uwe Haberkorn with the highly recognized “The Stifterverband Science Award – Erwin Schrödinger Prize” of the Helmholtz Association. He was involved in the development of the theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), PSMA-914 and PSMA-1007 (approved as Radelumin). His research interests focus on radiopharmaceutical cancer research and radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide production and radionuclide theranostics; targeted endoradiotherapy; and noninvasive molecular imaging. His scientific output includes more than 275 publications (Scopus) and over 20 and 45 (EPO & USPTO) published patent monographs, respectively.